Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
Jae Cheol Jo, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan Sik Park, Jooryung Huh, Sang Wook Lee, Jin Sook Ryu, Cheolwon Suh
Dive into the research topics of 'Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma'. Together they form a unique fingerprint.